BerandaLAURUSLABS • NSE
Laurus Labs Ltd
₹467,00
27 Sep, 16.00.40 GMT+5.30 · INR · NSE · Pernyataan Penyangkalan
SahamSekuritas terdaftar di IN
Tutup sebelumnya
₹463,20
Rentang hari
₹459,05 - ₹472,90
Rentang tahun
₹349,40 - ₹518,00
Kapitalisasi pasar
252,00 M INR
Volume Rata-Rata
2,45 jt
Rasio P/E
170,26
Hasil dividen
0,17%
Bursa utama
NSE
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(INR)Jun 2024Perubahan Y/Y
Pendapatan
11,95 M1,11%
Biaya operasional
5,90 M13,96%
Laba bersih
125,10 jt-49,66%
Margin laba bersih
1,05-50,00%
Penghasilan per saham
0,23-50,00%
EBITDA
1,60 M1,31%
Tarif pajak efektif
33,02%
Total aset
Total liabilitas
(INR)Jun 2024Perubahan Y/Y
Investasi tunai jangka pdk
1,42 M192,30%
Total aset
Total liabilitas
Total ekuitas
41,16 M
Saham yang beredar
543,91 jt
Harga terhadap nilai buku
6,07
Tingkat pengembalian aset
Tingkat pengembalian modal
2,53%
Perubahan kas bersih
(INR)Jun 2024Perubahan Y/Y
Laba bersih
125,10 jt-49,66%
Kas dari operasi
Kas dari investasi
Kas dari pembiayaan
Perubahan kas bersih
Arus kas bebas
Tentang
Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients, generic formulations, custom synthesis, biotechnology, veterinary APIs and agrochemicals. The company was founded in 2005 by Satyanarayana Chava. Laurus Labs has its eight manufacturing plants located at Visakhapatnam, Hyderabad and Bangalore. The manufacturing units have received one or more approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA. The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers. The R&D centres are based in Hyderabad, Visakhapatnam and United States. Wikipedia
Didirikan
2005
Karyawan
6.007
Telusuri
Hapus penelusuran
Tutup penelusuran
Aplikasi Google
Menu utama